[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tertiary-hyperparathyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tertiary-hyperparathyroidism":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100515922","parathyroid-tumor-clonal-status-100515922",false,"NCT05997810","Parathyroid Tumor Clonal Status","A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)","Inclusion Criteria:\n\n* 1\\. Diagnosed with hyperparathyroidism (primary, secondary, or tertiary), biochemically confirmed (e.g., serum calcium and\u002For intact PTH consistent with the underlying etiology), and undergoing clinically indicated management\n* Female and male patients\n* Age ≥ 18 years\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* Patients with a history of cervicofacial irradiation.\n* Patients currently taking lithium or with a history of lithium use.\n* Pregnant patients",true,"FEMALE","18 Years","80 Years",{"count":21,"type":22},839,"ESTIMATED","OBSERVATIONAL","To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).",[26,27,28,29],"Parathyroid Tumor","Primary Hyperparathyroidism","Secondary Hyperparathyroidism (SHPT)","Tertiary Hyperparathyroidism","RECRUITING","2026-05-07",{"date":33,"type":34},"2026-05-12","ACTUAL",{"date":36,"type":34},"2023-07-28",{"date":38,"type":22},"2032-01-31",{"name":40,"class":41},"Washington University School of Medicine","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100557761","intraoperative-parathyroid-hormone-monitoring-to-guide-surgery-in-renal-hyperparathyroidism-100557761","NCT06542315","Intraoperative Parathyroid Hormone Monitoring to Guide Surgery in Renal hyperparathyroIdism","Intraoperative Parathyroid Hormone Monitoring to Guide Surgery in Renal hyperparathyroIdism: A Pilot Trial","PEREGRINE","Inclusion Criteria:\n\n* 18 years of age or older\n* Candidate for subtotal parathyroidectomy or total thyroidectomy with or without autotransplantation\n* Tertiary hyperparathyroidism and\u002For recurrent hyperparathyroidism OR secondary hyperparathyroidism diagnosed with any stage of chronic kidney disease\n\nExclusion Criteria:\n\n* Undergoing parathyroidectomy for primary hyperparathyroidism\n* Pregnant or breastfeeding women\n* Undergoing revision parathyroidectomy\n* Undergoing minimally invasive or video-assisted parathyroidectomy\n* Unable to provide written consent to be participant in study\n* Unable to complete study follow-up visits","ALL",{"count":53,"type":22},60,"INTERVENTIONAL",[56],"NA","The goal of this pilot clinical is to determine the feasibility of a fully powered clinical trial to determine the effectiveness of intraoperative parathyroid hormone (IOPTH) criteria in guiding surgery for secondary and tertiary hyperparathyroidism. The main question it aims to answer is:\n\nIs a fully powered trial investigating the role for IOPTH criteria in secondary and tertiary hyperparathyroidism feasible?\n\nThe comparison group is surgery not guided by IOPTH.\n\nParticipants will be randomized to undergo parathyroid surgery with one of four IOPTH criteria or a control arm that does not use IOPTH. All recruited patients are asked to complete quality of life and cognitive questionnaires, in addition to bloodwork during the study period.",[59,29],"Secondary Hyperparathyroidism",[61,62,63,64,65,66],"hyperparathyroidism","secondary hyperparathyroidism","tertiary hyperparathyroidism","chronic kidney disease","renal transplantation","pilot trial","NOT_YET_RECRUITING","2024-08-04",{"date":70,"type":34},"2024-08-07",{"date":72,"type":22},"2024-10",{"date":74,"type":22},"2026-06",{"name":76,"class":41},"McMaster University"]